Immune T-cells of the CAR T-cell therapy CT103A are able to rapidly eliminate disease-driving immune cells and reduce immune cells’ overall inflammatory activity in people with neuromyelitis optica spectrum disorder (NMOSD), a study shows. “This study is the first in-depth single-cell … analysis of multiple types of body fluids…
CT103A CAR T-cells
The CAR T-cell therapy CT103A appears safe generally and may ease disability and improve the quality of life in adults with relapsed or refractory neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4), according to data from a small Phase 1 clinical trial. “In this…
Recent Posts
- Review shows approved treatment sharply cuts relapse risk in NMOSD
- Choosing courage and connection after the trauma of NMOSD
- NMOSD patients report lower sleep quality, study shows
- The bra line battle is a wardrobe crisis for women with NMOSD
- New antibody may explain mystery cases of NMOSD-like disease